initi coverag
recoveri neutral
sentiment cynosur recoveri balanc mute growth margin
stock sinc februari cynosur deal peer
henc evid cynosur final improv expect posit
catalyst bullish sculpsur expect doubl digit aesthet segment
growth suffer fda recal drag beyond see path
compani grow struggl see go higher combin limit
visibl toward futur margin expans risk larg contract renegoti
support initi neutral despit inexpens valuat low sentiment
ub evid lab cosmet surgeon focus primarili non-invas fat
reduct market sculpsur product compet categori volum growth
robust expect remain bullish sign though better salesforc
execut need separ expect acceler molecular diagnost growth
due menu expans dilig support though roch remain
upsid downsid potenti
could make us bullish better margin expans detail support
futur gain faster diagnost growth new menu ou growth stay stronger
longer larg contract get renew limit price concess cynosur growth
pressur diagnost larg contract loss cynosur keep stumbl
valuat discount dcf primari method
discount cash flow primari valuat method cross-check impli
trade multipl dcf incorpor wacc lt growth
assumpt yield price target dcf impli ntm price-to-earnings
 multipl current ntm price-to-earnings
averag ntm price-to-earnings
trade data key metric
compani account thomson reuter ub estim metric mark ub analyst adjust appli valuat base averag share price year base
share price oct edt
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid
report singl factor make invest decis
 cynosur acquisit materi under-perform expect
busi rebound deliv growth
 growth slow low singl digit current profil deliv
acceler mid singl digit manag hope
initi coverag holog inc octob
ub research thesi map guid think report
 cynosur acquisit materi under-perform expect busi
rebound deliv growth manag expect
ye see low doubl digit growth aesthet cynosur divis given end market
dynam impact stabl salesforc new division manag compani
renew emphasi turn busi around said forecast low singl digit
growth given declin women segment fda product recal issu
 growth slow low singl digit current profil deliv acceler
mid singl digit manag hope
see lower end compound-annual-growth-rate achiev thru though given fda
recal issu import driver breast health fear dramat step seem overdon
molecular diagnost virolog opportun present upsid larg contract renew risk
ou result sustain given larg untap market rel share gain
weak cynosur result pressur stock under-perform healthcar peer
sinc acquisit improv cynosur result continu strong ou revenu
acceler diagnost growth posit stock howev given drag model
growth combin modest margin leverag larg contract
risk lead neutral rate
doctor/aesthet practition ub evid lab survey posit sculpsur bodi
contour product posit tempsur envi mix picosur dilig lab
director support view virolog opportun intens model inform breast health
consensu forecast come reflect fda relat recal
organ growth estim compound-annual-growth-rate use revers dcf stock
reflect modest futur growth margin expans growth ebit margin thru
upsid downsid
compani descript holog inc sell diagnost instrument kit medic imag system surgic
product aesthet product emphasi women health
initi coverag holog inc octob
stock significantli lag peer sinc feb
ub evid lab survey cosmet surgeon point
signific growth non-invas fat reduct market
good news sculpsur yy procedur growth
dx
scenario contact
sourc exhibit compani data ub research
upcom contract renew best case price
ntm price-to-earnings rel
initi coverag holog inc octob
 cynosur acquisit materi
under-perform expect busi
rebound deliv growth
ye see growth acceler low doubl digit aesthet
cynosur divis given end market dynam impact stabl
salesforc new division manag compani renew emphasi
turn busi around said forecast low singl digit
growth given drag declin women segment due
ub evid lab survey custom plastic surgeon cosmet
dermatologist practition larg focus non-invas fat
reduct market sculpsur product reflect rapidli grow
market sculpsur hold market posit market share look
rel stabl feedback picosur product mix
interest grow new tempsur envi product
consensu forecast growth averag next three year
aesthet divis use revers dcf estim longer term stock
cynosur medic aesthet divis remain drag growth
yet show doubl digit growth manag forese though
sever area bright spot ytd
breast health perform better expect ytd
impress intern expansion/growth continu
molecular diagnost segment continu deliv new
compani point strength opportun busi
compris revenu medic aesthet appropri focal
area investor
tackl debat section key driver outlook opinion
insight
aesthet repres revenu weak perform
sinc deal along natur busi one that less medic
clinic intens lower barrier entri one histor
initi coverag holog inc octob
sensit market prone aggress sale tactic plu lower margin
key factor weak rel stock perform compani
figur peer stock perform sinc cynosur transact feb
ub factset compani report peer compani list proxi
stock date measur day prior announc
cynosur acquisit compar averag return
diagnost med tech life scienc tool peer list proxi
cynosur deal/weak factor would argu
biggest one
result turn around perform cynosur reach doubl
digit level growth manag outlin sustain growth
contribut toward total compani result would help fortifi investor
confid manag strateg decision-mak capit alloc
decis catch peer impli stock price recoveri
initi coverag holog inc octob
figur cynosur organ growth weaken right time
want understand cynosur key driver assess
weak conduct dilig provid insight toward potenti recoveri
sub-seg skin largest area nearli larger
segment close size
figur medic aesthet cynosur revenu distribut segment
growth across segment weak across board
bodi weakest follow women skin
initi coverag holog inc octob
figur medic aesthet cynosur segment growth sinc acquisit
amongst differ cynosur platform product stand
largest revenu base current along biggest futur opportun
along make current/futur revenu base sculpsur
singl biggest factor
high temperatur laser design reduc fat non-invas
picosecond laser one trillion second remov tattoo
fraction laser treatment menopaus women
radio-frequ devic use non-abl techniqu skin
although perform segment weak worth
explor understand set primarili understand sculpsur
initi coverag holog inc octob
primari focu product manag time
deal
weak relat sculpsur cite numer call
manag sinc deal
largest singl product factor
commiss custom survey ub evid lab focus
non-invas fat reduct market sculpsur market also assess
competit posit market dynam pertain picosur
let cut chase offer summari front find
explor import detail survey section
non-invas fat reduct market grow rapidli look set
continu rapid growth posit
sculpsur player tight amongst custom
survey posit though top player lead signific
sculpsur market share expect remain fairli stabl neutral
lack salesforc interact factor hinder sculpsur new
custom penetr posit
plan purchas new/addit sculpsur mute neg
net see survey posit perform beyond
aesthet cynosur segment support growth
unfortun recent fda inquiri market claim numer
women laser product includ mona lisa touch notabl drag
cynosure-rel growth address risk impact
debat focu remain discuss debat upon survey
outlook cynosur ex recent fda issu
ub evid lab survey aesthet custom major
plastic surgeon nearli respond own practic
year experi averag
initi coverag holog inc octob
one bullish statist survey recent expect
growth non-invas fat reduct nifr market
figur growth nifr volum signific mean median
well high teen growth goal manag set deal
time cynosur transact manag discuss bodi
contour nifr market fastest grow non-invas aesthet
categori procedur place togeth skin tighten togeth
categori total depict grown compound-annual-growth-rate sinc
project growth rate
american academi plastic surgeri track statist mani
surgic non-surg procedur conduct across unit state
recent data also point rapidli grow nifr market
initi coverag holog inc octob
figur nifr growth volum yy
figur nifr non-surg procedur
american societi aesthet plastic surgeri asap
procedur conduct
american societi aesthet plastic surgeri asap
search realself com non-surg laser treatment reduct fat
return treatment across provid point market larg divers
arguabl quit fragment ub evid lab survey queri
respond prefer across compet platform identifi
awar reason high across platform
said practition survey far select term
platform own use treatment
initi coverag holog inc octob
figur platform practic survey offer sculpsur
figur share in-offic nifr procedur platform sculpsur
distant
allergan coolsculpt via zeltiq acquisit greatest brand
awar nearli lead offic instrument share well
procedur share liposonix sculpsur virtual
tie survey
interest ask respond top factor
chose use certain product top factor consist efficaci sustain fat
reduct eas use anoth common top choic abl
glean survey number behind coolscupt domin
 respond see superior fat reduct eas
use
initi coverag holog inc octob
figur top factor underpin choic top nifr platform
eas use
bodi area
eas use
eas use
figur survey distribut sustain fat reduct use sculpsur
reduct fat sculpsur achiev averag sculpsur user
in-lin reduct seen sculpsur trial fda approv
initi coverag holog inc octob
figur eas use efficaci return invest cite factor
buy nifr platform ask respond list top factor
sculpsur saw direct chang share higher
tick lower though number statist signific
coolsculpt saw share trend higher similarli bigger drop
though chang statist signific appear
platform outsid top gain traction though sinc
didnt pick one specif platform gain hard draw conclus
figur nifr share trend sculpsur lead platform expect see
share loss small sculpsur bigger leader coolsculpt
initi coverag holog inc octob
term new instrument purchas survey point modest gain
sculpsur current remain year next year
well howev given small bit level signific
figur sculpsur unit own plan buy modest new
buy
buy
sinc dont histor purchas year sinc launch march
user imposs know translat absolut purchas
intent yoy growth rate suffic say ad unit per year
deceler user base compar ad
past year could group earli adopt big bolu unit
addit slower henc fine comparison
inquir nearli half respond base familiar
sculpsur current instrument key factor
prevent adopt sculpsur
inferior
inferior roi
inferior
inferior
initi coverag holog inc octob
respons question clear posit grant
non-custom find product either overhyp doesnt perform spec
lack attract
said reason non-own lack awar driven
lack salesforc interact
given rapid salesforc turnov partli voluntari increasingli involuntari
accord manag factor caus weak
sculpsur also aesthet product line fix issu open
account toward potenti new placement opportun accord
manag issu clearli address expect turn
tailwind beyond team matur new aesthet
find pretti meaning salesforc turnov amongst respond
custom new rep within past month know
rep posit rep month
steadi rep year given small bit
level signific
figur cynosur aesthet sale rep turnov exist custom
rep new within
rep steadi
know
rep new within
sale rep
interest survey pick major disloc sculpsur result
past month contrast weak result compani
post name sinc acquir cynosur despit signific
turnov instanc evalu current/futur usag purchas plan
custom depend upon sale rep relationship didnt see much
nonetheless given signific turnov lack sale calls/product
knowledg reason custom familiar sculpsur arent
buy speak opportun ahead
amongst user doctors/practition see solid patient satisfact
sculpsur
initi coverag holog inc octob
figur patient satisfact sculpsur answer provid
given small number figur bit level signific
nifr volum outlook robust acceler per survey
sculpsur posit vendor look in-tact product
expect maintain share
hold share see market volum grow would drive upsid
ours/consensu publish forecast
market expans new custom limit result
though fix salesforc drive awar understand
biggest factor see posit impact given
beyond sculpsur also inquir usag trend relat two
cynosure/holog devic name picosur tempsur envi
picosur picosecond laser initi traction tattoo remov
sinc expand broader skin revit use remov wrinkl
pigment accord manag usag tattoo remov
though tattoo remov rel small market accord data
american societi aesthet plastic surgeri picosur fda approv sinc
market leader accord survey
initi coverag holog inc octob
figur market share tattoo remov amongst respond
dig outlook amongst owner picosur tattoo remov small
sampl size limit abil draw strong conclus result amongst
owner current expect procedur volum strong yy
consist well satisfact level high
picosur approv beyond tattoo remov name product also use
treat acn scar fine line wrinkl pigment lesion per manag
skin rejuven market compris picosur usag broader market
skin rejuven materi larger tattoo grow
slightli faster rate per data american societi aesthet plastic surgeri
figur yy chang procedur volum
american societi aesthet plastic surgeri
initi coverag holog inc octob
figur tattoo remov market tini compar broader skin
american societi aesthet plastic surgeri
picosur market share per ub evid lab survey larger skin
significantli lower tattoo remov
given usag occur product result surpris
sinc dont futur share expect suffic say outlook
picosur mix result look forward gather addit
new tempsur envi product util radiofrequ rf head deep
layer skin creat collagen tighten skin remov wrinkl
product launch januari
initi coverag holog inc octob
product approv skin relat product tempsur vitalia
launch women channel though discuss earlier product
recent pull market wake fda industri inquiri
regard label market
surprisingli individu survey yet awar
tempsur envi product round topic interest/knowledg
tempsur envi major remain respond still educ
final view product similar inferior exist
product feel superior
figur view tempsur envi awar low awar
still educ
compar
inferior exist
superior exist
custom awar tempsur current futur
ownership outlook profil would argu encourag regard expect
initi coverag holog inc octob
figur buy plan amongst respond awar tempsur
buy next
sinc number actual owner found small refrain
draw meaning conclus regard outlook amongst
expect procedur growth use envi yy
expect
final impress outlook tempsur envi skin therapi per
awar low see posit opportun
custom awar tempsur henc big
arguabl easi opportun increas awar
similar sculpsur revamp stabl salesforc
new aesthet manag focu qualiti
sale approach provid signific target opportun
amongst respond awar tempsur
alreadi devic
major plan buy least one devic next
feedback construct amongst small base owner
regard usag growth sampl size small
initi coverag holog inc octob
juli fda issu public statement sent letter number
manufactur includ laser energi base devic regard
market claim made devic involv vagin rejuven
procedur name agenc concern devic market
indic approv pose possibl harm
receiv letter regard relat monalisa touch laser
compani subsequ august announc decis continu sell
monalisa touch seek clariti agenc though decid
suspend market distribut recent launch tempsur vitalia
handpiec probe area although letter product
receiv vitalia product recent launch fda clearanc
compani market devic heat vagin tissu
manag felt best take action confirm meet
regulatori requir devic categori tempsur system remain
fda-clear continu use indic
earli septemb manag provid financi guidanc
action call revenu impact includ lost sale
vitalia custom rebat vitalia impact lower monalisa touch
sale revenu guidanc compani maintain within
origin guidanc rang given base busi strength ep expect
low end origin rang
initi coverag holog inc octob
 growth slow low singl digit
current profil deliv acceler mid
singl digit manag hope
see lower end compound-annual-growth-rate achiev thru though
given fda recal issu import driver breast health fear
dramat step overdon molecular diagnost
opportun present upsid larg contract renew risk ou
result assum sustain given larg untap market
dilig lab expert molecular diagnost dx busi detail
model analysi breast health busi scenario analysi
explor variou lever growth breast ou us box placement
diagnost virolog opportun
consensu assum organ growth prior fda recal
differ baselin estim
estim use revers dcf stock reflect
modest futur growth margin expans growth
gain confid path sustain growth
ceo steve macmillan join ceo decemb
tomosynthesi cycl earli life-cycle within quarter take
compani growth rate acceler flattish upper singl
digits/low doubl digit propel larg part impact new
box placement sinc peak organ growth gradual
deceler reach lowest level recent slow
box placement along tough comp associ earlier
strength key factor
initi coverag holog inc octob
manag continu view compani mid-single-digit grower despit
recent weaker trend get back rang remain primari
focu abil acceler growth msd rang key futur stock
perform consid sever questions/top dilig
key busi segment product could enabl return
mid-singl growth end compani
invest thesi margin also gradual declin
signific opportun revers trend improv outlook
front margin matter point
 also becom bigger focu balanc sheet order
debt/ebitda manag eager leverag compani
lead brand strong channel add product much
 impact busi stock
build bigger better busi profil ou primari focal
point current manag result date impress
current growth trajectori continu moder pace
expect given larger absolut size
long steadi declin organ growth combin manag
confid focu return msd lead us conclud
degre compani acceler growth key question analyz
make call stock
initi coverag holog inc octob
segment growth quit volatil
compani busi segment face factor
contribut swing growth rate thu numer potenti
factor investig regard drive acceler forward growth
breast health diagnost two largest segment zero
area key toward analys growth potenti possibl
sourc elev total growth msd rang
growth dynam differ busi contribut toward
compani organ growth slowdown breast health diagnost
focu area analysi instruct review extent
differ busi grown growth impact compani
total organ growth segment revenu exposur breast held steadi
diagnost declin via blood screen divestitur made
initi coverag holog inc octob
figur segment exposur breast health diagnost largest segment
peak us box placement impact
signific compani organ growth slip low singl
digit lsd rang breast health meaning segment see
improv growth yy
figur segment experienc slow growth
initi coverag holog inc octob
figur drive growth year saw segment weaken bar total repres organ
growth year segment block repres much organ growth segment contribut year effect
segment organ growth segment revenu
notabl step-down organ growth compani
reflect three issu mainli
drag aesthet weak comp
slowdown surgic novasur
slowdown molecular diagnost us
factor combin drag offset impact
improv breast
breast health outlook expect moder averag last year
thereaft
result ytd stronger expect busi grow
averag thru first quarter includ acceler core
growth though stack comp basi growth stabl
quarter breast health tale piec
us box growth penetr share price slow greatest risk
downsid
ou box placement mix still strong
servic steadi solid
intervent breast strong upsid potenti
us placement scrutin segment within compani
initi coverag holog inc octob
model moder growth bia downsid
manag remain confid us box placement forecast
quarter look continu see cliff sight
mamo box us left convert remain long runway growth
good news
said adopt advanc hospit
alreadi taken place compani reliant upon convers
smaller hospit turn
lead greater placement compani lower end mammographi
instrument carri price discount
reflect earli adopt adopt henc placement rate
natur difficult
addit market share impress captur new
placement could continu risk slippag vs
upsid us mammographi box placement repres total breast
imag sale total breast health degrad mix
price lower end system impact bh organ growth
ou placement recent ou result europ major
success stori breast molecular dx particular within
breast health divis ou repres revenu current
year ago breast ou grown last quarter distributor
acquisit help growth
potenti placement opportun greater us
mammographi instal base though exist base instrument
analog thu upgrad opportun much analog
note compani ou placement split
analog custom convert share mammographi instrument
eu significantli less us
initi coverag holog inc octob
rate growth reason project ou breast health recent
surg last quarter manag think sustain
expect sustain also implicitli
servic often over-look servic repres meaning portion global
breast sale total servic revenu breast grew
ytd averag year prior assum servic
grow hsd go forward though given recent strength could conserv
intervent breast growth bright spot back
introduct affirm prone biopsi tabl brevera biopsi system
potenti market opportun signific dilig
warrant assess realist build pipelin innov
critic variabl ceo macmillan strategi along continu ou success
serv diversifi revenu stream beyond box placement-
affirm full year launch brevera first year
replac cycl unit forecast impli reach max penetr
end year henc suggest materi upsid assumpt exist
impact organ
ab interv
addit compani move offens regard tuck
debt leverag reason spot faxitron revenu digit
specimen radiolog technolog breast conserv surgeri acquir
juli recent focal therapeut revenu
technolog improv breast conserv surgeri announc septemb
yet close compani plan activ tuck strategi
expect deal fill faster grow adjac gener salesforc
leverag accret organ growth rate
initi coverag holog inc octob
key driver breast health
number annual us box placement rate ou breast
arguabl variabl influenc futur rate breast
busi see chang variabl
influenc rate global breast health revenu figur show
sensit factor global breast forecast
figur sensit breast health organ growth ou
put togeth
gener total breast health growth
model growth slow ou slow comp
moder slow us upsid exist ou growth sustain
intervent product penetr ramp faster plu impact tuck deal
alreadi complet futur one
diagnost outlook expect pick-up growth diagnost
revenu ex blood assum modest slow thereaft
segment within compani diagnost vastli differ growth rate
molecular diagnost piec robust growth wherea overal
result look materi wors given drag cytolog addit slower
grow blood busi divest grifol
initi coverag holog inc octob
figur diagnost dx organ growth ex blood divestitur weak moder
molecular diagnost nearli sole contributor segment growth
recent year particular prior blood roll-off pressur report
figur diagnost organ growth contribut molecular mdx
exclud blood screen even clearer molecular diagnost mdx
remain sole driver segment growth
initi coverag holog inc octob
figur mdx driver growth cytolog negligible/dmal drag
expect pick-up gradual slow thereaft
virolog upsid arm full us approv virolog
test divis increasingli see impact
beyond fulli enter categori
women risk increas competit core
women health franchis pose headwind cphd own
see success per check
market leader roch full menu coba
platform us serv new risk
deal though impact could take time
pama risk lab deal fallout price pressur
medicar book busi potenti
exert pressur back dx vendor share
pressur earli check larg lab manag howev
indic success thu far optim low abil
get dx oem share pressur although price pressur may
arriv dx peer acceler
share larger refer lab due pama drag given
panther platform signific exposur mani
mid-siz lab may look sell/partn larger
refer lab result diminish profit
key uncertainti re-negoti
contract quest labcorp estim
repres diagnost
revenu quest bigger contract
ascrib revenu amount specif custom
decis immin contract
compani
initi coverag holog inc octob
term pass june manag
recent comment final decis larg
custom contract announc prior
upcom confer call time lh
uncertain suspect also
compani optimist success renew
quest dilig suggest odd favour
incumb nonetheless loss contract
renew signific price concess
realist repres risk compani analysi
reflect impact price cut
outright loss show one year
possibl contract retain price impact
could spread
expect roch would bid aggress
built quest lab corp
understand roch full women health menu
approv still need hpv
unclear much factor would
approv higher throughput machin
would make decis
assum decrement margin lead
ep hit even maintain like necessit
pretti big price cut result impact revenu
much modest unclear much
risk reflect stock today would
argu much outright loss
factor impact scenario
dx
scenario contact
dx
scenario contact
initi coverag holog inc octob
growth stagnant given domin market share
on-going interv extens result
expect slightli declin market compani
like grow slightli faster henc cytolog remain drag
forese futur nearli dx segment
revenu ex blood pose materi drag overal
segment total growth
virolog test market global market us
recent januari secur final fda approv hbv
molecular panther platform global incumb roch lead share
abbott though look make inroad vs player expect
ripe opportun given rel weaker diagnost
platform instrument also weaker menu
initi check us lab director reflect willing engag
ass rel merit adopt virolog importantli check
price larger lab alreadi util roch unlik switch henc
biggest opportun mid-siz lab panther use
alreadi instead send virolog test decid
move volum onto panther
us market near term opportun given understand contract turn
frequent result evalu share gain
us ou given slower turnov assum contract
renew everi year win avail deal
seem reason particularli exist custom add
total organ growth everi year ramp molecular diagnost
forecast assum step growth vs though
year stack basi slight deceler henc implicitli give
compani credit success virolog similarli healthi
initi coverag holog inc octob
figur virolog opportun win renew add
total organ growth thu insignific opportun
renewal/yr
renewal/yr
impact dx organ impact/yr
impact organ impact/yr
put togeth implicitli given credit virolog
opportun mdx growth rate improv
upsid base upon analysi
assum greater win rate forecast
impact contract loss aggress price time
summari arriv organ growth actual
given fda recal low end manag msd organ growth goal
feel forecast balanc area upsid ou breast health mdx
virolog impact cynosur growth sustain greater contribut
tuck deal turn organ though also sever risk area dgx/lh
initi coverag holog inc octob
primari valuat method discount cash flow arriv price
target review methodolog input
unlik life scienc tool compani coverag trade around
midpoint histor valuat rang absolut basi
rel basi trade averag tool end market robust growth
averag seen slower growth part due
initi coverag holog inc octob
figur ntm price-to-earnings rel
figur ntm ev/ebitda rel
discount cash flow primari valuat metric arriv price
target valuat base upon wacc lt growth
assumpt util explicit forecast period includ detail
financi model intermedi forecast beyond
saniti check dcf analysi assess forward price-to-earnings price target multipl
impli price target impli price-to-earnings multipl rel price-to-earnings appli
ntm ep forecast compar current ntm price-to-earnings
initi coverag holog inc octob
million us except per share amount
invest work capit
equiti
assum cost debt
debt end current year
end current year
net debt cash end current year
dilut sharecount end current year
capital-expenditure revenu
chang wc chang revenu
current month fiscal year
market valu equiti
rel impli current
initi coverag holog inc octob
upsid downsid
upsid upsid case assum virolog share gain
greater expect ou breast health continu rapid growth combin
new product strength drive organ growth combin
good increment margin enabl ep estim stock
multipl expand recent high price-to-earnings
base expect compani navig thru temporari fda recal
issu molecular diagnost breast health continu show
improv help new menu sustain ou traction
core cynosur rebound deliv growth assum organ growth
ex recal issu come dcf model yield price target
assum organ growth intermedi growth
downsid downsid case assum compani lose
diagnost contract repres largest custom lead signific
neg margin leverag combin continu cynosur sale issu
pressur organ growth along flat ebit
margin ep
initi coverag holog inc octob
kit medic imag system surgic product
aesthet product emphasi women health
compani oper five segment diagnost
breast health medic aesthet gyn surgic
skelet health sell bone densitomet
base marlborough massachusett
core vitro dx market alreadi consolid
think molecular dx consolid begin
well price alway key challeng
think like get even tougher novel content
creat competit dynam industri
signific chang propos
regulatori standpoint potenti signific futur
reimburs cut suggest dynam difficult time
dx test supplier believ creat plenti
opportun nimbl investor
initi coverag holog inc octob
ub evid lab provid research analyst rigor primari research team
conduct repres survey key sector decision-mak mine internet systemat
collect observ data pull inform innov sourc appli
varieti advanc analyt techniqu deriv insight data collect valuabl
resourc suppli ub analyst differenti inform support forecast
recommendationsin turn enhanc abil serv need client
ub evid lab conduct on-line survey plastic/cosmet surgeon plastic
surgeon cosmet dermatologist cosmet surgeon aesthet practition
gener derm respond survey perform non-invas fat reduct
practic practition practic practition averag
year practic
initi coverag holog inc octob
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
initi coverag holog inc octob
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
initi coverag holog inc octob
valuat method risk statement
discount cash flow primari valuat method cross-check
impli trade multipl dcf incorpor wacc lt
growth assumpt yield price target dcf impli ntm price-to-earnings
 multipl current ntm price-to-earnings
year averag ntm price-to-earnings
risk revenu growth includ possibl cynosur never regain
momentum due fda problem salesforc turnov competit also
placement could declin dramat due market satur compani also
face risk intern growth stall compani lose share loss
molecular diagnost compani experi price pressur molecular
initi coverag holog inc octob
